A citation-based method for searching scientific literature

Raymond R Townsend, Israel Machin, Jimmy Ren, Angelina Trujillo, Masato Kawaguchi, Ujjwala Vijapurkar, Chandrasekharrao V Damaraju, Michael Pfeifer. J Clin Hypertens (Greenwich) 2016
Times Cited: 57



Despoina Vasilakou, Thomas Karagiannis, Eleni Athanasiadou, Maria Mainou, Aris Liakos, Eleni Bekiari, Maria Sarigianni, David R Matthews, Apostolos Tsapas. Ann Intern Med 2013
Times Cited: 505




List of shared articles



Times cited

SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature.
Konstantinos Imprialos, Charles Faselis, Chrysoula Boutari, Konstantinos Stavropoulos, Vasilios Athyros, Asterios Karagiannis, Michael Doumas. Curr Pharm Des 2017
10

Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease.
Kazuomi Kario, Keith C Ferdinand, James H O'Keefe. Prog Cardiovasc Dis 2020
12

The Effect of Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors on Cardiometabolic Profile; Beyond the Hypoglycaemic Action.
Eirini Lioudaki, Emmanouil S Androulakis, Martin Whyte, Konstantinos G Stylianou, Eugenios K Daphnis, Emmanouil S Ganotakis. Cardiovasc Drugs Ther 2017
6

Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes - A systematic review.
Karin RĂ„dholm, Jason Hy Wu, Muh Geot Wong, Celine Foote, Gregory Fulcher, Kenneth W Mahaffey, Vlado Perkovic, Bruce Neal. Diabetes Res Clin Pract 2018
41

Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?
Konstantinos P Imprialos, Chrysoula Boutari, Konstantinos Stavropoulos, Michael Doumas, Asterios I Karagiannis. J Neurol Neurosurg Psychiatry 2017
25

Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists.
C Berra, R Manfrini, D Regazzoli, M G Radaelli, O Disoteo, C Sommese, P Fiorina, G Ambrosio, F Folli. Pharmacol Res 2020
3

Cardiovascular Effects of Sodium Glucose Co-transporter-2 Inhibitors in Patients with Type 2 Diabetes Mellitus.
Surender Kumar, Pradeep G Talwalkar, Sambit Das, Soumik Goswami. Indian J Endocrinol Metab 2019
1




Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension.
Ilkka Tikkanen, Robert Chilton, Odd Erik Johansen. Curr Opin Nephrol Hypertens 2016
26



The effect of SGLT2 inhibitors on cardiovascular events and renal function.
Konstantinos P Imprialos, Konstantinos Stavropoulos, Michael Doumas, Asterios Karagiannis, Vasilios G Athyros. Expert Rev Clin Pharmacol 2017
7


Medical management of resistant hypertension: the role of sodium-glucose cotransporter 2 inhibitors (SGLT2i).
Muhannad Alqudsi, Juan Carlos Q Velez, Jose Navarrete. Curr Opin Cardiol 2021
0



An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes.
Joseph A Messana, Stanley S Schwartz, Raymond R Townsend. Vasc Health Risk Manag 2017
5